Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Aug 1;14(4):676-679.
doi: 10.21037/hbsn-2025-316. Epub 2025 Jul 25.

Beyond chemotherapy in biliary tract cancer: a closer look at the updated long-term follow-up data of the TOPAZ-1 trial

Alexander Olkus  1   2   3 , Michael T Dill  2   3
Affiliations
Editorial

Beyond chemotherapy in biliary tract cancer: a closer look at the updated long-term follow-up data of the TOPAZ-1 trial

Alexander Olkus et al. Hepatobiliary Surg Nutr. .
No abstract available

Keywords: Immunotherapy; biliary tract cancer (BTC); long-term survival.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-2025-316/coif). A.O. reports honoraria for presentations from AstraZeneca; support for attending meetings from Abbvie; and stock options in bioNTech ADR and Novo-Nordisk. M.T.D. reports grants from AstraZeneca, Gilead, Dr. Falk Pharma, Ipsen, Jazz Pharmaceuticals, and Pliant Therapeutics; consulting fees from AstraZeneca and Eisai; honoraria from AstraZeneca and Roche; and support for attending meetings from Dr. Falk Pharma and AstraZeneca. The authors have no other conflicts of interest to declare.

Comment on

References

    1. Valle JW, Kelley RK, Nervi B, et al. Biliary tract cancer. Lancet 2021;397:428-44. 10.1016/S0140-6736(21)00153-7 - DOI - PubMed
    1. Roos E, Soer EC, Klompmaker S, et al. Crossing borders: A systematic review with quantitative analysis of genetic mutations of carcinomas of the biliary tract. Crit Rev Oncol Hematol 2019;140:8-16. 10.1016/j.critrevonc.2019.05.011 - DOI - PubMed
    1. Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 2020;17:557-88. 10.1038/s41575-020-0310-z - DOI - PMC - PubMed
    1. Rizzo A, Carloni R, Frega G, et al. Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center. Curr Oncol 2022;29:5084-90. 10.3390/curroncol29070402 - DOI - PMC - PubMed
    1. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-81. 10.1056/NEJMoa0908721 - DOI - PubMed

LinkOut - more resources